drugset

drugset / Trial / NCT06781255

Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

NCT06781255 ↗

Phase 1 Terminated 1 enrolled Michelle Abou-Jaoude Inflammasome Therapeutics · collab

NaSingle-groupOpen-labelTreatment

Summary

A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).

Timeline

Start: 2025-03-13
Primary completion: 2026-02-25
Completion: 2026-02-25

Outcome

Outcome not reported

Stopped (Enrollment): “Low recruitment outcome”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Kamuvudine-9	Unknown	96 mg	Oral

Indications